دورية أكاديمية
First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq
| العنوان: | First-Line Biologic Therapy and Obesity in Moderate-to-Severe Psoriasis: Results from the Prospective Multicenter Cohort Psobioteq |
|---|---|
| المؤلفون: | Assan, Florence, Tubach, Florence, Arlegui, Hugo, Viguier, Manuelle, Beylot-Barry, Marie, Dupuy, Alain, Beneton, Nathalie, Joly, Pascal, Jullien, Denis, Mahe, Emmanuel, Paul, Carle F, Richard, Marie-Aleth, Bachelez, Herve, Giboin, Caroline, Chosidow, Olivier, Sbidian, Emilie |
| المساهمون: | Hôpital Henri Mondor, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Robert Debré, Bordeaux Research In Translational Oncology Bordeaux (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP), École des Hautes Études en Santé Publique EHESP (EHESP), Centre Hospitalier Le Mans (CH Le Mans), Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Edouard Herriot CHU - HCL, Hospices Civils de Lyon (HCL), Centre Hospitalier Victor Dupouy, Centre d'investigation clinique de Toulouse (CIC 1436), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Marseille, Imagine - Institut des maladies génétiques (IHU) (Imagine - U1163), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hopital Saint-Louis AP-HP (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), French Ministry of Health PHRC AOM 09 195, French National Agency for the Safety of Medicines and Health Products (ANSM), Abbvie, MSD France, Janssen Johnson and Johnson USA Janssen Biotech Inc, Pfizer Pfizer, Departement a la Recherche Clinique et au Developpement (DRCD - Department for Clinical Research and Development), Assistance Publique - Hopitaux de Paris (Paris Hospitals), French Society of Dermatology, Psoriasis Research Group |
| المصدر: | ISSN: 1018-8665. |
| بيانات النشر: | HAL CCSD Karger |
| سنة النشر: | 2021 |
| المجموعة: | Université Toulouse III - Paul Sabatier: HAL-UPS |
| مصطلحات موضوعية: | Psoriasis, Obesity, Biologic therapy, Drug survival, Psobioteq, [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Background - Obesity is associated with an increased risk of psoriasis. Objective - In this study, we examined whether body mass index (BMI) is taken into account when choosing first-line biologic therapy for psoriasis. Methods - In this cohort study, we compared obese (BMI ≥30 kg/m2) and non-obese patients for the first-line biologic therapy prescribed, its survival, reasons for discontinuation, therapy optimization, co-prescription of methotrexate and factors associated with long drug survival. Results - A total of 931 patients were included: 594 (64%) were male, median age was 46 years (interquartile range 36-56). The most-prescribed biologic agents as first-line treatment were adalimumab (ADA; 42.7%), ustekinumab (UST; 29.9%) and etanercept (ETA; 22.9%); only frequency of infliximab (IFX) prescription differed between groups. Drug survival was significantly shorter for obese than non-obese patients (p < 2.10-4) and was worse for obese than non-obese patients for UST (p = 0.009) and ETA (p = 0.02), with no difference for ADA (p = 0.11). The main reason for discontinuation was primary inefficacy (62%), which was more frequent in obese than non-obese patients. The cumulative incidence of optimization did not significantly differ between the groups, except for ADA (SHR 1.91, 95% CI [1.23-2.96], p = 0.005). On multivariate analysis, risk of discontinuation was associated with only ETA as first-line biologic therapy (HR 1.51, 95% CI 1.04-2.19). Conclusion - This study highlighted the lack of difference in prescription of first-line biologic treatment, except for IFX, between obese and non-obese patients presenting moderate-to-severe psoriasis. Drug survival in obese patients is shorter, mainly because of inefficacy, than in non-obese patients. This highlights the need for targeted pharmacological studies in obese individuals to find optimal administration schemes. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33535213; hal-03156232; https://hal.science/hal-03156232Test; PUBMED: 33535213 |
| DOI: | 10.1159/000513398 |
| الإتاحة: | https://doi.org/10.1159/000513398Test https://hal.science/hal-03156232Test |
| رقم الانضمام: | edsbas.E8B69214 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1159/000513398 |
|---|